Figure 1.
Flow chart showing study design and study population size at baseline and follow-ups.
Table 1.
Basic inclusion criteria (Eligibility criteria L1) for volunteers enrolled for the study.
Table 2.
Eligibility Criteria L2 comprising of core behavioral measures (CBM), Beck Depression Inventory (BDI), Mini Mental State Examination (MMSE), Lake Louise Score for Acute Mountain Sickness and baseline characteristics for kidney function, lipid profile, liver function and blood glucose.
Table 3.
Physiological Characteristics at baseline and during different durations of stay at high altitude.
Figure 2.
Percentage prevalence of mild cognitive impairment in study population during baseline and follow-ups.
Percentage of participants with mild cognitive impairment (MCI) increased progressively with duration of stay at high altitude.
Table 4.
Assessment of cognitive impairment using Mini Mental State Examination (MMSE), Multi Domain Cognitive Screening Test (MDCST), Raven Standard Progressive Matrices (RSPM), Clock Drawing Test (CDT), Bender Visual Motor Gestalt Test (BGT), Facial Recognition Test (FRT), Serial Digit Learning test (SDLT), Stroop Color Word Interference Test-TBAG Form (SCWT), Verbal fluency test (VFT), Visual-aural digit span test-B (VADS-B) during baseline and follow-ups.
Figure 3.
Representative brain maps of alpha, beta and delta components of EEG of the same participant during baseline and follow-ups.
Scale bar shows regional activity in mkV.
Table 5.
Amplitudes (µV) of EEG wave components at different electrode positions.
Figure 4.
Population distribution of a) Homocysteine b) Vitamin B12 and c) Folic acid during baseline and follow-ups.
* denotes P-value <0.001 when compared to baseline data.
Table 6.
Correlation of homocysteine, vitamin B12 and folic acid with mild cognitive impairment.